The risk of death has decreased by 42% with a new mRNA vaccine against skin cancer

A recent phase 3 clinical trial of the mRSN vaccine developed by Moderna and Merck showed promising results in reducing melanoma recurrence and mortality risk by 42%. Previous phase 2 trials reported a 49% reduction, indicating the vaccine's effectiveness. The vaccine also decreased the risk of melanoma metastasis by 38%. While survival data is still pending, researchers noted favorable trends. Side effects were consistent with earlier studies, including fatigue and injection site pain. The companies are in discussions with U.S. authorities for potential approval. Other companies like BioNTech and Roche are also developing similar mRNA vaccines for melanoma, currently in early clinical stages.